Abstract
Abstract Pritumumab is a natural human IgG1 kappa antibody that has been derived from a B-cell isolated from a regional draining lymph node of a patient with cervical carcinoma. Specificity analysis of the antibody with human tissues showed the target antigen, altered tumor-associated vimentin, to be highly restricted to various epithelial cancers and not normal cells and tissues. Daunomycin-pritumumab conjugates were generated that increased the effectiveness of the antibody. In various phase II clinical trials in Japan 249 patients with brain cancer were treated with unconjugated pritumumab. The overall response rate was between 25-30%, a 9-fold increase over standard care, with several survivors beyond 5-years post-treatment. The patients were on a low dose regimen of 1mg given twice a week for a course of 24 weeks for a total dose of 48 mgs per course. Pritumumab appears to be a safe and effective therapy in patients with brain cancer. Citation Format: Mark C. Glassy, Rishab Gupta. Pritumumab, a natural human IgG antibody defines a tumor-associated biomarker useful in treating brain cancer patients. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2553. doi:10.1158/1538-7445.AM2014-2553
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
